Amazon Gets Into Boner Pill Business, Hims Stock Goes Limp
Hims & Hers Stock Drops After Amazon Says It Will Offer Hair-Loss Treatments
Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and erectile dysfunction, directly competing with the telehealth startup. Amazon on Thursday launched the treatments through its One Medical telehealth service,
Amazon announced Prime members can access new upfront pricing for treatment of five common conditions such as erectile ...
BofA lowered its rating of Hims & Hers (HIMS) to underperform from buy, citing Amazon’s (AMZN) push into the hair loss and ...
Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...
In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...
Walt Disney’s earnings beat Wall Street estimates, Super Micro Computer extends losses, and Cisco posts fiscal first-quarter ...
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Hims & Hers (HIMS) is down -17.7%, or -$4.88 to $22.72. Published first on TheFly – the ultimate source for real-time, ...
Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...
Amazon One Medical is rolling out a new service to provide Prime members access to clinical treatments for common health and ...
The tech giant said it would offer upfront, monthly pricing for customers seeking consultations and medications for five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback